Form 4: Werewolf Therapeutics Director Plans Future Stock Sales

Ansbert Gadicke, a director and 10% owner of Werewolf Therapeutics, along with affiliated entities, has filed a Form 4 detailing planned sales of 195,666 shares of common stock in late November 2025 under a Rule 10b5-1 plan.

Summary

• Ansbert Gadicke, a director and 10% owner of Werewolf Therapeutics, Inc. (HOWL), and several affiliated entities, reported planned sales of common stock.
• The transactions are scheduled to occur pursuant to a Rule 10b5-1 plan established on September 24, 2025.
• On November 21, 2025, a planned sale of 64,331 shares of common stock is reported at a weighted average price of $0.83 per share, with prices ranging from $0.80 to $0.8861.
• On November 24, 2025, a planned sale of 88,802 shares of common stock is reported at a weighted average price of $0.98 per share, with prices ranging from $0.8733 to $1.03.
• On November 25, 2025, a planned sale of 42,533 shares of common stock is reported at a weighted average price of $0.92 per share, with prices ranging from $0.90 to $0.99.
• Following these planned transactions, the total indirect beneficial ownership by the reporting persons will be 5,125,770 shares.
• The shares are held across various entities including MPM Asset Management LLC (352,045 shares), MPM BioVentures 2014, L.P. (2,223,199 shares), MPM BioVentures 2014(B), L.P. (148,284 shares), MPM Asset Management Investors BV2014 LLC (76,522 shares), MPM Oncology Innovations Fund, L.P. (487,501 shares), and UBS Oncology Impact Fund L.P. (1,838,219 shares).

Sentiment

Score: 3

Explanation: The planned sale of shares by a director and 10% owner, along with affiliated entities, is generally viewed negatively as it signals a reduction in insider ownership. However, the transactions are conducted under a pre-established Rule 10b5-1 plan, which suggests the sales are not based on new, non-public information, mitigating the immediate negative signal.

Negatives

• The planned sale of 195,666 shares by a director and 10% owner, along with affiliated entities, represents a reduction in insider ownership.
• The weighted average sale prices for the planned transactions range from $0.83 to $0.98 per share, which are relatively low.

Risks

• Future insider selling, even if pre-planned, can be perceived negatively by the market and potentially impact investor confidence.
• A reduction in beneficial ownership by a significant insider and affiliated funds could lead to questions about long-term commitment to the company.

Future Outlook

na

Industry Context

na

Related Party Transactions

• The transactions involve Ansbert Gadicke, a director and 10% owner, and several affiliated entities including MPM Oncology Innovations Fund LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, and MPM Asset Management LLC. These entities are interconnected through various general partner and management relationships, with Ansbert Gadicke holding key roles across them. Each reporting person disclaims beneficial ownership of the securities except to the extent of their pecuniary interest therein.

Stakeholder Impact

• Shareholders may perceive the planned insider selling as a negative signal, potentially impacting investor confidence.
• The future reduction in beneficial ownership by a significant insider and affiliated funds could lead to questions about long-term commitment, although the sales are pre-planned.

Key Dates

Recommendation

The planned sale of shares by a director and 10% owner, Ansbert Gadicke, and affiliated entities, is generally a bearish signal. However, the transactions are scheduled to be executed under a pre-established Rule 10b5-1 plan, which indicates the sales were planned in advance and not necessarily driven by new, adverse material non-public information. Given the absence of other financial or operational updates in this filing, a 'hold' recommendation is appropriate, advising investors to monitor future company developments and broader market conditions for Werewolf Therapeutics.

Keywords

Werewolf Therapeutics, HOWL, Insider Transaction, Form 4, Stock Sale, Ansbert Gadicke, MPM BioImpact, 10b5-1 Plan, Biotechnology, Pharmaceuticals